- Home
- APLS vs MLYS Comparison
APLS vs MLYS Comparison
Compare APLS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- MLYS
- Stock Information
- Founded
- APLS 2009
- MLYS 2019
- Country
- APLS United States
- MLYS United States
- Employees
- APLS N/A
- MLYS N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- MLYS Health Care
- Exchange
- APLS Nasdaq
- MLYS Nasdaq
- Market Cap
- APLS 2.9B
- MLYS 2.9B
- IPO Year
- APLS 2017
- MLYS 2023
- Fundamental
- Price
- APLS $20.39
- MLYS $40.40
- Analyst Decision
- APLS Buy
- MLYS Strong Buy
- Analyst Count
- APLS 19
- MLYS 6
- Target Price
- APLS $32.83
- MLYS $46.40
- AVG Volume (30 Days)
- APLS 3.4M
- MLYS 1.5M
- Earning Date
- APLS 10-30-2025
- MLYS 11-10-2025
- Dividend Yield
- APLS N/A
- MLYS N/A
- EPS Growth
- APLS N/A
- MLYS N/A
- EPS
- APLS 0.36
- MLYS N/A
- Revenue
- APLS $1,016,397,000.00
- MLYS N/A
- Revenue This Year
- APLS $25.39
- MLYS N/A
- Revenue Next Year
- APLS N/A
- MLYS N/A
- P/E Ratio
- APLS $56.77
- MLYS N/A
- Revenue Growth
- APLS 42.11
- MLYS N/A
- 52 Week Low
- APLS $16.10
- MLYS $8.24
- 52 Week High
- APLS $35.72
- MLYS $47.65
- Technical
- Relative Strength Index (RSI)
- APLS 39.49
- MLYS 49.69
- Support Level
- APLS $18.93
- MLYS $36.56
- Resistance Level
- APLS $30.48
- MLYS $47.65
- Average True Range (ATR)
- APLS 1.29
- MLYS 3.45
- MACD
- APLS -0.37
- MLYS -0.00
- Stochastic Oscillator
- APLS 13.94
- MLYS 50.18
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.